|
Originally published In Press as doi:10.1074/jbc.M002362200 on May 11, 2000
J. Biol. Chem., Vol. 275, Issue 33, 25608-25615, August 18, 2000
Relative Spatial Position of a Snake Neurotoxin and the Reduced
Disulfide Bond (Cys192-Cys193) at the 
Interface of the Nicotinic Acetylcholine Receptor*
Sophie
Michalet §,
Fatima
Teixeira ¶,
Bernard
Gilquin ,
Gilles
Mourier ,
Denis
Servent ,
Pascal
Drevet ,
Patrice
Binder ,
Socrates
Tzartos**,
André
Ménez , and
Pascal
Kessler 
From the CEA/Saclay, Département
d'Ingénierie et d'Etudes des Protéines, 91191 Gif-sur-Yvette, France, DGA/DSP-STTC, 26 Bd Victor, 00460 Armées, France, and the ** Hellenic Pasteur Institute, 127 Vassilisis Sofias Avenue, 11521 Athens, Greece
Received for publication, March 20, 2000, and in revised form, May 8, 2000
 |
ABSTRACT |
We determined the distances separating five
functionally important residues (Gln10,
Lys27, Trp29, Arg33, and
Lys47) of a three-fingered snake neurotoxin from the
reduced disulfide bond (Cys192-Cys193)
located at the  interface of the Torpedo nicotinic
acetylcholine receptor. Each toxin position was substituted
individually for a cysteine, which was then linked to a maleimido
moiety through three different spacers, varying in length from 10 to 22 Å. We estimated the coupling efficiency between the 15 toxin
derivatives and the reduced cystine (192-193) by gel
densitometry of Coomassie Blue-stained gels. A nearly quantitative
coupling was observed between Cys192 and/or
Cys193 and all probes introduced at the tip of the first
(position 10) and second (position 33) loops of Naja
nigricollis -neurotoxin. These data sufficed to locate the
reactive thiolate in a "croissant-shaped" volume comprised between
the first two loops of the toxin. The volume was further restrained by
taking into account the absence or partial coupling of the other
derivatives. Altogether, the data suggest that Cys192
and/or Cys193, at the  interface of a
muscular-type acetylcholine receptor, is (are) located in a volume
located between 11.5 and 15.5 Å from the -carbons at positions 10 and 33 of the toxin, under the tip of the toxin first loop and close to
the second one.
 |
INTRODUCTION |
The nicotinic acetylcholine receptor
(nAChR)1 is a transmembrane
protein, composed of five subunits ( 2  for the
muscular type), which represents the prototype of the ligand-gated ion channels. It is quasi-irreversibly blocked by snake curarimimetic toxins, a feature which helped in the isolation and purification of the
receptor almost three decades ago. However, only recently has some
light been shed on the molecular interaction between snake toxins and
the nAChR. At least 10 residues of a sea snake toxin are involved in
binding to the receptor from Torpedo marmorata, i.e. Gln7, Ser8, Gln10,
Lys27, Trp29, Asp31,
Arg33, Ile36, Glu38, and
Lys47 (1, 2). Receptor regions that interact with snake
toxins have also been investigated in various studies. Some lines of evidence indicate that snake toxins can bind to two sites located at
the interfaces of the  - and  -subunits (3-5). Among the different receptor regions that may be implicated in toxin binding, the
domain 180-200 of the -subunit is clearly an important determinant (for a review see Ref. 6). It is also involved in various other binding
functions, because it is recognized by small organic agonists (7) and
small antagonists (8-12). More recently, double mutant cycle analyses
have revealed a number of contacts that may occur between nAChR and a
cobra curarimimetic toxin (13-15). Thus, Arg33 of NmmI
toxin is coupled to the receptors Val188 and
Leu119, whereas the toxin Lys27 interacts
with Glu176, and to a lesser extent with
Tyr190, Pro197, and Asp200.
Although double mutant cycle analyses have evaluated the distances between various charged residues of this short-chain toxin and some
residues of the receptor -subunit (15), the relative positioning of
the toxin with respect to the receptor -subunit still remains unclear. To address this question, we have estimated the distances that
separate several functionally important toxin residues from Cys192 and/or Cys193, two residues that belong
to the critical binding region 180-200 of the two -subunits. More
precisely, we used experimental conditions that allowed us to perform
this study at a single binding site, namely, the site at the  interface.
It is known that the disulfide bond
(Cys192-Cys193) can be selectively reduced
without affecting antagonist binding (16) and hence specifically
labeled with irreversible antagonists (8, 17, 18) or agonists (19).
Treatment of the receptor with bromoacetylcholine or
[4-(N-maleimido)benzyl]trimethylammonium iodide (MBTA) in
the presence of a disulfide reducing agent leads to the covalent
modification of one or both -subunits, depending on the
concentration of affinity label (20-22). Even more interestingly perhaps, when the reducing agent is eliminated before the alkylation step, only one site is labeled by both probes, independent of their
concentrations (22). This site has been demonstrated to correspond to
the high affinity binding site of d-tubocurarine (23), which
was later located at the  interface of the receptor (11, 24).
Using radioactive MBTA, it was further demonstrated that
Cys192 and Cys193 are the exclusively
labeled residues (8).
Our strategy was inspired from this site-directed alkylation procedure.
First, we chemically engineered analogues of a curarimimetic snake
toxin, by automated peptide synthesis. More precisely, we individually
replaced each of the five functional residues Gln10,
Lys27, Trp29, Arg33, and
Lys47 by a cysteine residue. The reason for the choice of
these residues was that they are both important binding contributors to
toxin-receptor formation and are widely spread over the functional
topography of the snake toxin (1, 2). Second, we linked each of them to
three spacers of different lengths (10, 14, and 22 Å) that always
ended in a maleimido group. Third, each of the 15 monomodified toxin
derivatives was mixed with the receptor whose
(Cys192-Cys193) disulfide bond was
selectively reduced and affinity-labeled under conditions where only
the  interface was modified (23). Fourth, the coupling yield was
estimated from gel electrophoresis experiments. Fifth, the data were
exploited to build a model in which the toxin was positioned relative
to cysteines 192 and/or 193 of the -subunit at the  interface.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Peptides were synthesized with an Applied
Biosystems 433 apparatus, using Fmoc-protected amino acids of the
highest purity commercially available from Novabiochem or Advanced
Chemtech. N,N'-(1,2-phenylene)dimaleimide and
N,N'-(1,4-phenylene)dimaleimide were from
Aldrich, and
N,N'-bis(3-maleimidopropionyl)-2-hydroxy-1,3-propanediamine was from Sigma. [ -125I]bungarotoxin (Bgtx) (200 Ci.mmol 1) was from Amersham Pharmacia Biotech. Live
T. marmorata were from the Station Biologique d'Arcachon
(France). Naja nigricollis horse antivenom serum was from
the Institut Pasteur (France). Goat anti-rat (GAR-PO) and rabbit
anti-horse (RAH-PO) IgG peroxidase conjugates were from Jackson
ImmunoResearch Laboratories (West Grove, PA). Electrospray mass
spectrometry was carried out using a Quattro II spectrometer
from Micromass. Circular dichroism spectra were recorded on a Jobin
Yvon CD6 dichrograph at 22 °C.
HPLC Conditions--
Reverse-phase high performance liquid
chromatography (HPLC) purifications were done with a Vydac C4
semipreparative column (10 × 250 mm; flow rate, 4 ml.min 1; linear gradient, 5% to 21% B in 6 min; then
21% to 27% B in 19 min (A, H2O 0.1% trifluoroacetic
acid; B, CH3CN 0.06% trifluoroacetic acid)).
Membrane Preparations--
nAChR-rich membranes from the
electric tissue of T. marmorata were prepared, as described
previously (25), in the presence of 20 mM
N-ethylmaleimide to block all free cysteines. They were further purified by alkali treatment (26). The concentration of
acetylcholine binding sites was measured at equilibrium with [ -125I]Bgtx (27).
Synthesis of Toxin Analogues--
N. nigricollis
-toxin analogues were synthesized as described earlier (28-30) and
refolded with 1.5-15 mM oxidized dithiothreitol (DTT)
overnight, under inert atmosphere. The refolded toxins were purified by
reverse-phase HPLC as described above, and checked by electrospray mass
spectrometry and circular dichroism.
To conjugate the single free cysteine (Q10C, K27C, W29C, R33C, or K47C)
of each toxin mutant with dimaleimide reagents, we first solubilized
0.7 mg (0.1 µmol) of toxin analogue in 200 µl of 250 mM
sodium acetate buffer (pH 5.5)/2.5 mM EDTA and 100 µl of
H2O. The solution was then poured on 20 equivalents of
dimaleimide-containing reagent dissolved in either a mixture of
dimethylformamide (40 µl)/acetone (160 µl) for the two shorter
reagents (Mal10 and Mal14) or in 200 µl of sodium acetate buffer for
the longest (Mal22) reagent, with rapid stirring. The mixture was left
at room temperature for 30 min, except for the K27C derivatives, where
the incubation time was prolonged to 8 h. Excess reactant was
removed by exclusion chromatography (Biogel P2 from Bio-Rad), with the
toxin migrating in the void volume. Each maleimido-toxin derivative was
purified by HPLC as described above, and its mass was determined by
electrospray mass spectrometry.
Binding Assays--
Binding competition experiments were
performed at equilibrium, using [ -125I]Bgtx (200 Ci.mmol 1) as radioactive tracer. Varying amounts of
toxins were incubated in Ringer's buffer (5 mM sodium
phosphate buffer, pH 7, 250 mM NaCl, 5 mM KCl,
4 mM CaCl2, 2 mM MgCl2,
0.02% NaN3, 0.01% Triton X-100), with 0.3 nM
-toxin binding sites and 9 nM
[ -125I]Bgtx for 5 h at room temperature. The
mixture was filtered through Millipore filters (HAWP), which had been
soaked in the same buffer. The filters were rinsed twice with 5 ml of
Ringer's buffer and counted on a 1261-multigamma counter (Amersham
Pharmacia Biotech). Equilibrium dissociation constants were determined
from IC50 values according to Cheng and Prusoff (31).
Reduction of
(Cys192-Cys193)--
Selective reduction of
the (Cys192-Cys193) bond was carried out
using a slight modification of a previously described procedure (22).
Briefly, the nAChR (3.3 nmol of toxin binding sites) was incubated
under argon in degassed sodium phosphate buffer (100 mM, pH
7.6, 2.5 mM EDTA) containing 1 mM DTT, for 20 min at room temperature. The sample was centrifuged at 17,600 × g for 15 min at 4 °C. The supernatant was removed, and
the pellet was resuspended in 600 µl of degassed buffer A (250 mM sodium phosphate, pH 6.9, 2.5 mM EDTA) under
argon. The last step was reproduced twice to eliminate excess DTT, and
the pellet was resuspended in 1.1 ml of the same buffer, under argon.
Affinity Labeling--
For affinity-labeling experiments, the
reduced nAChR (1 µM toxin binding sites) was mixed with
each purified maleimido-toxin derivative (1 µM final
concentration) in buffer A (200-µl final volume). After 15- or 90-min
incubation at room temperature, under argon, each sample was
centrifuged as described above. The supernatant was removed, and the
pellets were resuspended in 70 µl of Laemmli buffer.
For protection experiments, the reduced receptor was first incubated
with native erabutoxin a (70 µM) for 2 h at room
temperature, under argon, before reaction with the maleimido derivatives.
Protection with Bromoacetylcholine--
After reduction, the
receptor was incubated with 10 µM bromoacetylcholine for
10 min at room temperature, under argon, in the presence of 5 µM tacrine (inhibition of acetylcholinesterase). The
receptor was then reacted as described above with R33C-Mal22 for 15 min.
SDS-PAGE and Immunoblots--
SDS-polyacrylamide gel
electrophoresis (PAGE) was performed according to Laemmli (32) using a
mini-protean apparatus (Bio-Rad). Briefly, about 30 µg of each
sample was electrophoresed on a 10% SDS gel of 1-mm thickness, which
was then stained with Coomassie Blue. For immunoblots, 3- to 10-µg
protein samples were subjected to SDS-PAGE and then transferred to a
polyvinylidene fluoride (PVDF) microporous membrane. The PVDF sheet was
quenched for 2 h at room temperature with buffer B (10 mM sodium phosphate, pH 7.4, 150 mM NaCl)
containing 2% bovine serum albumin. The sheet was incubated overnight
at 4 °C with monoclonal antibody 155 (33) (1/4000), or horse
antiserum to the venom (1 mg.ml 1) solubilized in 10 ml of
quench buffer. The PVDF membrane was washed (four times for 5 min) in
buffer B containing 0.1% Triton X-100. Peroxidase-labeled antibodies
GAR-PO or GAH-PO (1/4000) in 10 ml of quench buffer was added to the
PVDF membrane for 1 h at room temperature. The PVDF sheet was
washed again (four times for 5 min) in phosphate buffer containing
0.1% Triton X-100 and for 5 more min in the same buffer without
Triton. The solution containing the peroxidase substrate was used when
freshly prepared and consisted of 25 ml of phosphate buffer, 250 µl
of CoCl2 solution (30 g.l 1), and 25 µl of
H2O2 solution (30%). Development was stopped
by rinsing the membrane in water.
 |
RESULTS |
Preparation and Characterization of Cysteine-containing Toxin
Derivatives--
Toxin from N. nigricollis is amenable
to peptide synthesis on the micromole scale by automated Fmoc
solid-phase peptide synthesis (28-30). We thus prepared five toxin
derivatives in which the functionally important Gln10,
Lys27, Trp29, Arg33, and
Lys47 (1, 2) (Fig. 1) were
individually replaced by a cysteine. The deprotected peptides were then
reoxidized in the presence of oxidized DTT. The resulting proteins all
had a wild-type toxin secondary structure, as indicated by the
similarity of their CD spectra (Fig. 2).
The unique exception was the W29C derivative, which displayed no
positive peak at 230 nm, a finding that confirms that this band is
associated with a contribution of the tryptophan residue (34). Each
protein possesses a single cysteine, as assessed with Ellman's reagent
(35), and is characterized by the expected mass determined by
electrospray mass spectrometry (not shown). Up to 15 mg of each toxin
derivative was obtained, the overall average yield of synthesis being
about 5%. Therefore, none of the substitutions of any of the five
original functional residues by a cysteine altered the capacity of the
toxin to refold with its native-like secondary structure.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 1.
N. nigricollis
-neurotoxin. The structure has been taken from
Zinn-Justin et al. (51). The five residues, which were
individually replaced by a cysteine, are shown in boldface
font.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
Circular dichroism spectra of the five
"cysteine" analogues of N. nigricollis -neurotoxin
derivatives. The polypeptides were dissolved in water at 50 µM final concentration. The cell path length was 0.2 cm.
( ) native toxin, (- - -) Q10C, (- - -) K27C, (...) W29C,
(- · - · -) R33C, and ( · · · )
K47C.
|
|
As expected for residues that are critical for toxin binding to nAChR,
their replacement by cysteine caused binding affinity decreases (Table
I). The wild-type toxin had a
Ki of 13 pM, consistent with its
Kd value (36), and this value decreased 4-, 18-, 145-, 12-, and 29-fold upon use with mutations Q10C, K27C, W29C,
R33C, and K47C, respectively. Despite the affinity decreases, the
analogues still retained relatively high binding affinities.
View this table:
[in this window]
[in a new window]
|
Table I
Inhibition constants of N. nigricollis derivatives for T. marmorata
nAChR
Inhibition constants were obtained by competition at equilibrium
against -[125I]bungarotoxin (9 nM) on T. marmorata nAChR (0.3 nM toxin binding sites). Values
were estimated according to Cheng and Prusoff (31). Mean ± S.E.
or standard errors for two or more measurements.
|
|
Introduction of Maleimide-containing Reagents into
Cysteine-containing Toxins--
Three dimaleimides called Mal10,
Mal14, and Mal22 (Fig. 3) were reacted
with the additional cysteine introduced into each of the five toxin
mutants. To avoid formation of toxin dimers and to favor formation of
monomodified derivatives, we used a large excess of dimaleimides (20 eq). Excess reactant was subsequently eliminated by gel exclusion, and
the 15 derivatives were purified by reverse-phase HPLC. All but the
K47C-Mal10 derivative eluted as a single peak, which is strongly
indicative of their homogeneity. The K47C-Mal10 derivative HPLC profile
showed a slight but unexplained shoulder (not shown). All the
derivatives displayed the expected mass (not shown) and were used as
such for the labeling experiments.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 3.
Products obtained by coupling the free
cysteinyl residue of each toxin analogue with three different
dimaleimides in excess. One maleimide moiety has reacted with the
introduced thiol on the toxin, leading to a stable succinimidyl bond.
The second maleimide moiety is left for reaction with the reduced
receptor. The given distances correspond to the maximal length between
the cysteine -carbon and the reactive carbon on the maleimide
moiety.
|
|
All chemically modified derivatives but W29C displayed similar
affinities for nAChR as compared with cysteine-containing derivatives (Table I). Due to a lack of material, we could not determine the
IC50 values for W29C maleimido analogues. Interestingly,
the K27C-Mal22 derivative discriminated between the two toxin binding sites, one of them being recognized with almost the same affinity as
for the wild-type toxin and the other with an affinity approximately two orders of magnitude lower.
Affinity Labeling of the Reduced Receptor--
At first, all free
cysteines of a membrane preparation of nAChR were blocked using 20 mM N-ethylmaleimide. The nAChR possesses three
types of disulfide bonds spread over the extracellular domains of the
various subunits. These are Cys128-Cys142 on
all subunits, Cys192-Cys193 on the two
-subunits, and the Cys500-Cys500 on
the -subunits, linking two monomers of the receptor (37, 38). Under
mild reducing conditions, only the
(Cys192-Cys193) disulfide bond is
affinity-labeled (8), and if the reducing agent is eliminated before
the alkylation step, only the  interface is labeled (23). We
therefore carefully considered this procedure in a tentative
attempt to generate selective labeling of the reduced (Cys192-Cys193) bond at the  interface.
Incubation of the 15 maleimido-containing derivatives with the reduced
nAChR was analyzed by SDS-PAGE and revealed by Coomassie Blue staining
(Fig. 4A). The control lane
with no derivative (lane 1) shows the four expected nAChR
subunits. Clear changes in intensity patterns were only seen for all
derivatives modified at Q10C and R33C and for the derivative W29C-Mal22
(Fig. 4A; lanes 2, 3, 4, 10, 11, 12, and 13). In all
these cases, the intensity of the -subunit decreased. This change
was concomitantly associated with an increased intensity in the
-subunit, whose apparent molecular mass was close to 46 kDa,
which not only fits with the -subunit but also with a complex
consisting of an -subunit molecule associated with one toxin
molecule. No such clear-cut phenomenon was seen with the eight other
derivatives. Neither was it seen in control experiments where the
receptor was not reduced, nor when the reduced receptor was treated
with the well-known thiol blocking reagents N-ethylmaleimide
or 5,5'-dithiobis-(2-nitrobenzoic acid) (not shown). Moreover, when the
reduced nAChR was pretreated with an excess of an analogous snake
toxin, erabutoxin a, the effect vanished for all the derivatives,
except for the Q10C analogues for which the protection from affinity
labeling was around 80% (data not shown). These data indicate that the
phenomenon (i) is associated with the presence of free cysteines 192 and 193, (ii) requires a maleimido-containing toxin derivative, and
(iii) is specific to the introduced linkers located at positions 10, 29, and 33.

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 4.
Visualization of the labeling of the
-subunit of T. marmorata nAChR. The receptor was
reduced for 20 min with 1 mM DTT, at room temperature,
under argon atmosphere, in phosphate buffer (100 mM, pH
7.6, 2.5 mM EDTA). After three steps of centrifugation (see
"Experimental Procedures"), the reduced receptor (1 µM toxin binding sites) was incubated with the 15 toxin
analogues (1 µM) for 15 min at room temperature, under
argon atmosphere. A, Coomassie Blue staining of an SDS-PAGE
gel of the reduced nAChR after coupling with the 15 toxin derivatives.
10Å, 14Å, and 22Å represent the
Mal10, Mal14, and Mal22 linkers, respectively, on each cysteine
analogue. Reduced Torpedo membrane fragments (lane
1); same fragments after coupling with Q10C-Mal10 (lane
2), Q10C-Mal14 (lane 3), Q10C-Mal22 (lane
4), K27C-Mal10 (lane 5), K27C-Mal14 (lane
6), K27C-Mal22 (lane 7), W29C-Mal10 (lane
8), W29C-Mal14 (lane 9), W29C-Mal22 (lane
10), R33C-Mal10 (lane 11), R33C-Mal14 (lane
12), R33C-Mal22 (lane 13), K47C-Mal10 (lane
14), K47C-Mal14 (lane 15), and K47C-Mal22 (lane
16). Molecular weight markers (lane 17). B,
immunoblot with a horse serum directed against N. nigricollis venom. The lanes correspond to the same
derivatives as in A. C, immunoblot with
monoclonal antibody 155, a monoclonal antibody directed against the
nAChR -subunit. The lanes correspond to the same
derivatives as in A. D, inhibition of labeling by
R33C-Mal22 with 10 µM bromoacetylcholine
(BAC): reduced nAChR labeled with R33C-Mal22 (lane
a), reduced nAChR labeled with 10 µM BAC (lane
b), and reduced nAChR labeled with 10 µM BAC before
reaction with R33C-Mal22 (lane c).
|
|
To demonstrate that the toxin moiety was covalently associated with the
new 46-kDa protein band, we blotted an SDS gel previously incubated
with antitoxin antibodies present in a snake antivenom (Fig.
4B). Curiously, nonspecific detection was seen weakly at the
level of the -subunit and even more weakly around the -subunit (Fig. 4B, lane 1). Nevertheless, strong
differential labeling was readily observed around 46 kDa with
W29C-Mal22 and all the derivatives modified at Q10C and R33C. For all
these analogues, therefore, the toxin (molecular mass of 7 kDa)
migrates with an apparent mass of approximately 46 kDa. No such
detection was seen with other derivatives.
To establish whether the -subunit is also present in the new 46-kDa
band, we performed a similar blot experiment with an -subunit-specific monoclonal antibody (33) (Fig. 4C). The
control revealed an intense band migrating at the expected position of the free -subunit (40 kDa). An additional band was seen around 46 kDa with the three derivatives modified at Q10C and R33C and with the
longest derivative at W29C, confirming that, when these derivatives
were present, the -subunit migrated with a larger apparent molecular
mass. In other words, these particular toxin derivatives comigrated
with the -subunit, a finding that strongly indicated their covalent
association. We observed a similar though much weaker band with some
other derivatives, in particular with K27C-Mal22, the two shorter W29C
analogues, and the three K47C derivatives.
Coupling Yields at the  Interface Binding Site--
To
evaluate the coupling yield between toxin derivatives and the
-subunit at the  interface, we monitored the band intensities at both 39 and 46 kDa by densitometry of the Coomassie Blue-stained gel
for experiments where the reduced receptor and the derivatives were
incubated for 15 and 90 min. The densitometry data must obviously be
considered with caution, as they only reflect rough estimates of
coupling yields whose determination was further complicated by the
overlap of the intensity of the -subunit, which added to background
errors. However, these coupling yields seem to be in good agreement
with the sensitive -subunit immunoblot detection (Fig.
4C). Though the novel band at 46 kDa was not detectable by
immunoblot experiments for the two shorter derivatives at
Lys27 (Fig. 4C, lanes 5 and
6), a small coupling yield (around 10%) was determined by
gel densitometry (Fig. 5). We therefore
considered this value as the threshold above which coupling was
significant.

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 5.
Coupling yields of the various toxin
derivatives to the -subunit of the nAChR on
the  interface. The
labeling yields were estimated by gel densitometry (DensyLab,
Microvision Instruments, Evry, France) in each lane of Coomassie
Blue-stained gels, between the -subunit band and the 46-kDa band.
Comparing the intensity of the unreacted -subunit in each lane with
respect to the uncoupled receptor lane gave rise to equivalent results.
Due to a lack of precision of the method, related to high background
and superimposition of the -subunit band with the ( + toxin)
band, only labeling yields higher than 10% were considered as
representative. Two experiments were considered at different incubation
times between the reduced receptor and the 15 toxin analogues: 15 min
(gray) and 90 min (hatched) incubation.
10, 14, and 22 represent the Mal10,
Mal14, and Mal22 reactive linkers on each derivative Q10C, K27C, W29C,
R33C, and K47C. Error bars represent a 10% mean error
evaluated after several intensity measurements of each 39- and 46-kDa
band on each lane.
|
|
Irrespective of the position of the probe, no more than approximately
half of the two -subunits were labeled, showing that a single site
was labeled under our experimental conditions, where the reducing agent
was removed before reaction of the toxin (18, 21, 22, 39) (Fig. 5).
Furthermore, it is known that low concentrations of bromoacetylcholine
label the reduced receptor exclusively at the  interface (22,
23). In agreement with the view that the same site was probed by our
derivatives, we found that preincubation with a low concentration (10 µM) of bromoacetylcholine fully inhibited labeling with
R33C-Mal22 (Fig. 4D). Therefore, our data support the view
that the observed coupling occurs selectively on the reduced disulfide
at the  interface. The average 50% maximal coupling yield that
was observed with respect to both -subunits therefore corresponds to
100% labeling at the  interface (Fig. 5).
Fig. 5 shows that coupling yields obtained with Q10C-Mal22, W29C-Mal22,
and the three derivatives of R33C were approximately 100% after both
15- and 90-min incubations. This suggests that the maximal coupling was
reached within 15 min, in good agreement with an affinity-labeling
process (39). Fig. 5 also shows that each modified toxin position
behaved in a unique manner. At position 33, quantitative coupling was
observed irrespective of the size of the spacer. At position 10, a
70-80% coupling yield was seen with the two shorter linkers and
quantitative coupling with the Mal22 arm. At position 29, the coupling
yield was 30% and 45% with the Mal10 and Mal14 spacers, respectively,
and coupling was complete with the Mal22 spacer. Finally, the longest
probe at position 27 and the three probes at position 47 led to at most 20-30% coupling, whereas the two shorter arms at position 27 led to
virtually no coupling.
 |
DISCUSSION |
We prepared 15 derivatives of a snake toxin, each of them
possessing a single maleimido moiety. We used these derivatives to
localize the toxin spatially relative to cysteines 192 and/or 193 of
the reduced -subunit of the nAChR. Two lines of evidence indicated
that only cysteines at the  interface of nAChR were labeled.
First, previous data showed that, under the same experimental conditions as those used in this study, only half of the toxin binding
sites were labeled by a small receptor antagonist (8, 22, 40, 41).
Accordingly, we observed a maximal coupling yield of the -subunits
of approximately 50%. Second, data from several laboratories (11,
22-24) demonstrated that the labeled site is at the  interface,
this site being selectively discriminated by low concentrations of
bromoacetylcholine (22, 41). In agreement with these findings, we
observed that small amounts of the same reagent fully inhibit toxin labeling.
To interpret our coupling data in terms of relative positions between
the two receptor cysteines and the toxin, a number of assumptions had
to be made. First, because the two shorter spacers (Mal10 and Mal14)
are highly rigid, the maleimides located at their tips were considered
to describe a surface controlled by the movement of the spacers. We
assumed that the movement of the reactive carbons of the maleimides
encompassed the surfaces of two spheres with radii of 10 and 14 Å centered, respectively, on the -carbon of the modified residue.
Second, because we observed almost comparable full coupling with the
two shorter arms, we assumed that at least one of the thiolates of
cysteines 192 and 193 is present in a volume comprised between two
spheres with radii of approximately 11.5 and 15.5 Å (the distance
between the reactive carbon and thiols is assumed to be approximately
1.5 Å). We called these volumes the "reactive volumes."
Third, bearing in mind the imprecision of the data shown in Fig. 5, we
considered that the coupling yields with the two shorter arms at
positions 10 correspond approximately to full coupling, like those at
positions 33. Fourth, for partial but significant coupling, in the
range of 30-50%, as observed with W29C derivatives, we considered
that the reactive carbon was in proximity but not directly involved in
the reactive volumes. Fifth, because the longer arm is highly flexible,
we assumed it encompassed a large volume, which is difficult to
predict, separated at most by 22 Å from the C of the considered residue.
In addition to these assumptions, a number of elements had to be
considered. First, the coupling yield is influenced by the distance
that separates the thiols and the maleimides and by the accessibility
of the sulfhydryl which, for example, could be favorably (or
unfavorably) orientated for the attack of the thiolate perpendicularly to the plane of the maleimide ring. Second, at the molecular level, only one of the two cysteines can effectively react with the proposed maleimido group but, on average, a mixed population of labeled cysteines is likely to be generated, the relative proportion of labeled
cysteines probably varying from one derivative to another. Bearing all
these assumptions and considerations in mind, we interpreted our
coupling data in terms of possible distances separating cysteines 192 and/or 193 from the -carbon to which the reacting maleimido group
was linked.
With the Q10C and R33C derivatives, the two short linkers led to
virtually full coupling, so at least one of thiols 192 and 193 is
likely to be at the intersection of the two reactive volumes centered
on C 10 and C 33. The resulting volume adopted a
"croissant-like" shape (partially visible in Fig.
6B) located in between the
first and second loops almost perpendicularly to the plane of the large -sheet defined by the three toxin loops and orientated at nearly 45° from the axis of the central loop (Fig. 6A).
K47C-Mal22 showed almost no coupling, suggesting that the corresponding
C is more than 23.5 Å from the reactive thiol(s). We therefore
amputated the croissant-like area by about one fourth of its volume, in the region close to the second loop of the toxin. Interestingly, the
reactive carbon of the W29C-Mal14 derivative, which showed no more than
50% coupling, brushed against the remaining volume. In Fig. 6 we
colored violet the region of the remaining reactive volume,
which is located 15.5 Å from the C 29. In conclusion, the thiol(s)
of Cys192 and/or Cys193 at the  interface
of the reduced Torpedo nAChR, is(are) most likely to belong
to the remaining volume (colored yellow), in close proximity
to the violet zone, which is framed by the three maleimides
displayed by Q10C-Mal10, W29C-Mal14, and R33C-Mal10 (Fig. 6). Because
binding of the receptor antagonists does not seem to be affected by
reduction of the disulfide bond
(Cys192-Cys193) (16), we suggest that our
data also reflect the positioning of the toxin when bound to native
nAChR.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 6.
Putative position of the reactive thiol(s) of
the reduced
(Cys192-Cys193) disulfide
bond, on the  interface, with
respect to N. nigricollis -neurotoxin. N. nigricollis -neurotoxin skeleton is represented as an
orange tube. The five modified positions have been
visualized, i.e. 10, 27, 29, 33, and 47 with their
corresponding native residue label. A high temperature molecular
dynamics simulation (1000 K) of a dummy atom restrained by two
constraints, i.e. to be located between 11.5 and 15.5 Å from the C 10 and C 33 (full coupling with the two shorter linkers
for Q10C and R33C derivatives), engendered a croissant-like volume. A
filter, suppressing the area located at less than 23.5 Å from C 47
(no coupling with K47C-Mal22) restricted this volume to the depicted
dots. Another filter allowed us to visualize the area located at 15.5 Å from C 29 (partial labeling with W29C-Mal14) (violet
dots). All together, Q10C-Mal10 (labeled Gln10),
W29C-Mal14 (labeled Trp29), and R33C-Mal10 (labeled
Arg33) were drawn pointing at the most probable area of
localization of the reactive(s) thiolate(s) of Cys192
and/or Cys193. Because K27C and K47C derivatives did not
lead to any coupling to the reduced receptor, the original lysinyl
residues have been shown. A, view from the receptor face;
B, view from the bottom of the toxin.
|
|
Considering the rather large distance that separates the thiol(s)
occupying the identified region of the reduced receptor and the closest
toxin residues, Gln10, Arg33, and
Ile35, we suggest that the considered thiol(s) is(are) not
fully hidden when the toxin is bound to its receptor. This situation
could thus explain why the bound toxin does not fully protect labeling of the reduced receptor -subunit with bromoacetylcholine (42) or
N-ethylmaleimide.2
Probably, therefore, the reactive thiol(s) is (are) not in direct interaction with the toxin. Possibly also, the low coupling yields observed for the K27C and K47C derivatives (<30%) may be due to the
flexibility and/or the accommodation of the molecules during the
interaction between the receptor and toxin.
It was previously suggested that the positively charged quaternary
ammonium ion of the antagonist MBTA is located at about 10 Å from the
(Cys192-Cys193) disulfide bond (8). Based on
circumstantial evidence, it was also proposed that ammonium cations of
small organic ligands may be mimicked by the positive charge of
Arg33 of curarimimetic toxins (43, 44). Considering the
present data, Arg33 is indeed the only positively charged
toxin residue that is consistent with the proposed mimicry, the
positive charges of the two other candidates (Lys27 and
Lys47) being too remote from the disulfide bond.
How does our conclusion fit with previous experiments (13, 15, 45-47)
designed to position a short or a long-chain toxin with respect to
nAChR? An NMR study of a complex between the long-chain -Bgtx and a
dodecapeptide of the Torpedo receptor ( 185-196) indicated that the region 186-190 is located between the first and
the second loops of the toxin (46). Another NMR study of a complex
between -bungarotoxin and a library-derived peptide sharing some
similarity with the receptor peptide 187-199 showed that this
13-mer peptide also binds roughly in between the first and second toxin
loops. Both studies clearly agree with our findings that the receptor
region comprising (Cys192-Cys193) is located
in between the first and second loops of a snake toxin. In one study,
the peptide residues that are homologous to cysteines 192 and 193 were
too mobile to be located (46). In the other study (47), these residues
do not fit in the reactive region, but are located much more to the
back of the plane defined by the large -sheet of -bungarotoxin.
More precisely, the distance that separates the region colored
violet (Fig. 6) from those peptide residues is approximately
15 Å. This situation might result from differential binding between
short (this study) and long toxins (46, 47). Two lines of evidence
support this view. First, a derivative of a long-chain toxin modified
on the residue homologous to Lys27 with a mercurial
compound similar in length to our Mal14 derivative, slightly coupled to
the reduced cysteines of the -subunits (45), in contrast to our own
findings. Second, recent data have indicated that the binding
topographies of short- and long-chain neurotoxins for
Torpedo AChR are not strictly identical (48). It could also be argued that the small peptides used in NMR studies might behave differently when free or integrated in the whole receptor. More work is
needed to clarify this question.
Recently, double mutant cycle analyses have shown that when another
short toxin, NmmI, binds at the  interface of the non-reduced mouse muscular receptor, Arg33 of the toxin is in proximity
to Val188 and Tyr190 (13). This result
fully agrees with our proposed location of the disulfide bond
(Cys192-Cys193) at the same interface (Fig.
6). In addition, it was observed that Arg33 is also in
close proximity to Trp55 and Leu119 of the
-subunit of the muscular receptor (15). Assuming that the
Torpedo and mouse receptors are comparable, our data
combined with those of Osaka provide a molecular basis for the
positioning of a short-chain toxin relative to residues of the - and
-subunit at the  interface.
It is currently assumed that the sequential homology of
Asp174 and Asp180 is associated with an
identical position of the two residues in their respective sites (49).
Thus, a site-directed labeling experiment has shown that
Asp180 is located 1 nm from the reduced disulfide bond
(Cys192-Cys193) (38, 50). Furthermore,
Asp174 was recently located near Lys47 and
Lys48 on the third loop of NmmI toxin (15). Interestingly,
our model (Fig. 6) shows that the homologous Lys47 on
N. nigricollis toxin , and therefore the interacting
Asp174 (15), are over 10 Å from the disulfide bond at
the  interface. This evidence thus suggests that the binding
sites at the  and  interfaces are structurally distinct.
In conclusion, the data reported in this paper describe the respective
spatial positioning of an element of the nAChR and a snake toxin, a
potent receptor antagonist. Together with recent double mutant cycle
analyses (15), it offers a suitable molecular basis for building up the
remaining receptor elements that interact with the toxin.
 |
ACKNOWLEDGEMENT |
We thank Dr. H. Virelizier for
electrospray mass spectrometry measurements.
 |
FOOTNOTES |
*
This work was supported in part by the Association
Française contre les Myopathies.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a fellowship from the Direction de la Recherche et de
la Technologie from the Direction Générale des
Armées.
¶
Recipient of a fellowship from the Ministère de la
Recherche et de l'Enseignement Supérieure.

To whom correspondence should be addressed: Tel.:
33-1-69-08-52-25; Fax: 33-1-69-08-90-71; E-mail:
pascal.kessler@cea.fr.
Published, JBC Papers in Press, May 11, 2000, DOI 10.1074/jbc.M002362200
2
P. Kessler, personal observation.
 |
ABBREVIATIONS |
The abbreviations used are:
nAChR, nicotinic acetylcholine receptor;
Mal10, N,N'-(1,2-phenylene)dimaleimide;
Mal14, N,N'-(1,4-phenylene)dimaleimide;
Mal22, N,N'-bis(3-maleimidopropionyl)-2-hydroxy-1,3-propanediamine;
DTT, dithiothreitol;
HPLC, high performance liquid chromatography;
Bgtx, bungarotoxin;
PAGE, polyacrylamide gel electrophoresis;
PVDF, polyvinylidene fluoride;
Fmoc, N-(9-fluorenyl)methoxycarbonyl;
MBTA, [4-(N-maleimido)benzyl]trimethylammonium iodide.
 |
REFERENCES |
| 1.
|
Pillet, L.,
Trémeau, O.,
Ducancel, F.,
Drevet, P.,
Zinn-Justin, S.,
Pinkasfeld, S.,
Boulain, J. C.,
and Ménez, A.
(1993)
J. Biol. Chem.
268,
909-916
|
| 2.
|
Trémeau, O.,
Lemaire, C.,
Drevet, P.,
Pinkasfeld, S.,
Ducancel, F.,
Boulain, J. C.,
and Ménez, A.
(1995)
J. Biol. Chem.
270,
9362-9369
|
| 3.
|
Oswald, R. E.,
and Changeux, J. P.
(1982)
FEBS Lett.
139,
225-229
|
| 4.
|
Hervé, M.,
Pillet, L.,
Humbert, P.,
Trémeau, O.,
Ducancel, F.,
Hirth, C.,
and Ménez, A.
(1992)
Eur. J. Biochem.
208,
125-131
|
| 5.
|
Utkin, Y. N.,
Krivoshein, A. V.,
Davydov, V. L.,
Kasheverov, I. E.,
Franke, P.,
Maslennikov, I. V.,
Arseniev, A. S.,
Hucho, F.,
and Tsetlin, V. I.
(1998)
Eur. J. Biochem.
253,
229-235
|
| 6.
|
Arias, H. R.
(1997)
Brain Res. Rev.
25,
133-191
|
| 7.
|
Middleton, R. E.,
and Cohen, J. B.
(1991)
Biochemistry
30,
6987-6997
|
| 8.
|
Kao, P. N.,
Dwork, J. A.,
Kaldany, J. R. R.,
Wideman, S. J.,
Stein, S.,
and Karlin, A.
(1984)
J. Biol. Chem.
259,
11662-11665
|
| 9.
|
Dennis, M.,
Giraudat, J.,
Kotzyba-Hibert, F.,
Goeldner, M.,
Hirth, C.,
Chang, J. Y.,
Lazure, C.,
Chrétien, M.,
and Changeux, J. P.
(1988)
Biochemistry
27,
2346-2357
|
| 10.
|
Abramson, S. N.,
Li, Y.,
Culver, P.,
and Taylor, P.
(1989)
J. Biol. Chem.
264,
12666-12672
|
| 11.
|
Pedersen, S. E.,
and Cohen, J. B.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2785-2789
|
| 12.
|
Chiara, D. C.,
and Cohen, J. B.
(1997)
J. Biol. Chem.
272,
32940-32950
|
| 13.
|
Ackermann, E. J.,
Ang, E. T. H.,
Kanter, J. R.,
Tsigelny, I.,
and Taylor, P.
(1998)
J. Biol. Chem.
273,
10958-10964
|
| 14.
|
Osaka, H.,
Malany, S.,
Kanter, J. R.,
Sine, S. M.,
and Taylor, P.
(1999)
J. Biol. Chem.
274,
9581-9586
|
| 15.
|
Osaka, H.,
Malany, S.,
Molles, B.,
Sine, S.,
and Taylor, P.
(2000)
J. Biol. Chem.
275,
5478-5484
|
| 16.
|
Barrantes, F. J.
(1980)
Biochemistry
19,
2957-2965
|
| 17.
|
Karlin, A.,
and Winnik, M.
(1968)
Proc. Natl. Acad. Sci. U. S. A.
60,
668-674
|
| 18.
|
Karlin, A.,
and Cowburn, D.
(1973)
Proc. Natl. Acad. Sci. U. S. A.
70,
3636-3640
|
| 19.
|
Silman, I.,
and Karlin, A.
(1969)
Science
164,
1420-1421
|
| 20.
|
Karlin, A.
(1977)
Methods Enzymol.
46,
582-590
|
| 21.
|
Wolosin, J. M.,
Lyddiatt, A.,
Dolly, J. O.,
and Barnard, E.
(1980)
Eur. J. Biochem.
109,
495-505
|
| 22.
|
Walker, J. W.,
Richardson, C. A.,
and McNamee, M. G.
(1984)
Biochemistry
23,
2329-2338
|
| 23.
|
Ratnam, M.,
Gullick, W.,
Spiess, J.,
Wan, K.,
Criado, M.,
and Lindstrom, J.
(1986)
Biochemistry
25,
4268-4275
|
| 24.
|
Blount, P.,
and Merlie, J.
(1989)
Neuron
3,
349-357
|
| 25.
|
Saitoh, T.,
Oswald, R.,
Wennogle, L. D.,
and Changeux, J. P.
(1980)
FEBS Lett.
116,
30-36
|
| 26.
|
Neubig, R. R.,
Krodel, E. K.,
Boyd, N. D.,
and Cohen, J. B.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
690-694
|
| 27.
|
Schmidt, J.,
and Raftery, M. A.
(1973)
Anal. Biochem.
52,
349-354
|
| 28.
|
Mourier, G.,
Zinn-Justin, S.,
Trémeau, O.,
and Ménez, A.
(1996)
in
Peptides
(Epton, R.
, and Ramage, R., eds)
, pp. 659-660, Mayflower Scientific Ltd., Kingswinford, England
|
| 29.
|
Ruoppolo, M.,
Moutiez, M.,
Mazzeo, M. F.,
Pucci, P.,
Ménez, A.,
Marino, G.,
and Quéméneur, E.
(1998)
Biochemistry
37,
16060-16068
|
| 30.
|
Mourier, G.,
Servent, D.,
Zinn-Justin, S.,
and Ménez, A.
(2000)
Protein Eng.
13,
217-225
|
| 31.
|
Cheng, Y. C.,
and Prusoff, W. H.
(1973)
Biochem. Pharmacol.
22,
3099-3108
|
| 32.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685
|
| 33.
|
Tzartos, S. J.,
and Remoundos, M. S.
(1992)
Eur. J. Biochem.
207,
915-922
|
| 34.
|
Ménez, A.,
Bouet, F.,
Tamiya, N.,
and Fromageot, P.
(1976)
Biochim. Biophys. Acta
453,
121-132
|
| 35.
|
Ellman, G. L.
(1959)
Arch. Biochem. Biophys.
82,
70-77
|
| 36.
|
Weber, M.,
and Changeux, J. P.
(1974)
Mol. Pharmacol.
10,
1-14
|
| 37.
|
DiPaola, M.,
Czajkowski, C.,
and Karlin, A.
(1989)
J. Biol. Chem.
264,
15457-15463
|
| 38.
|
Czajkowski, C.,
and Karlin, A.
(1991)
J. Biol. Chem.
266,
22603-22612
|
| 39.
|
Karlin, A.,
McNamee, M.,
and Cowburn, D.
(1976)
Anal. Biochem.
76,
442-451
|
| 40.
|
Damle, V. N.,
and Karlin, A.
(1978)
Biochemistry
17,
2039-2045
|
| 41.
|
Damle, V.,
McLaughlin, M.,
and Karlin, A.
(1978)
Biochem. Biophys. Res. Commun.
84,
845-851
|
| 42.
|
Dunn, S. M.,
Conti-Tronconi, B. M.,
and Raftery, M. A.
(1993)
Biochemistry
32,
8616-8621
|
| 43.
|
Tsernoglou, D.,
and Petsko, G. A.
(1976)
FEBS Lett.
68,
1-4
|
| 44.
|
Tsernoglou, D.,
Petsko, G. A.,
and Hudson, R. A.
(1978)
Mol. Pharmacol.
14,
710-716
|
| 45.
|
Wohlfeil, E. R.,
and Hudson, R. A.
(1991)
Biochemistry
30,
7231-7241
|
| 46.
|
Basus, V. J.,
Song, G.,
and Hawrot, E.
(1993)
Biochemistry
32,
12290-12298
|
| 47.
|
Scherf, T.,
Balass, M.,
Fuchs, S.,
Katchalski-Katzir, E.,
and Anglister, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6059-6064
|
| 48.
|
Antil, S.,
Servent, D.,
and Ménez, A.
(1999)
J. Biol. Chem.
274,
34851-34858
|
| 49.
|
Martin, M.,
Czajkowski, C.,
and Karlin, A.
(1996)
J. Biol. Chem.
271,
13497-13503
|
| 50.
|
Czajkowski, C.,
and Karlin, A.
(1995)
J. Biol. Chem.
270,
3160-3164
|
| 51.
|
Zinn-Justin, S.,
Roumestand, C.,
Gilquin, B.,
Bontems, F.,
Ménez, A.,
and Toma, F.
(1992)
Biochemistry
31,
11335-11347
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. Teixeira-Clerc, A. Menez, and P. Kessler
How Do Short Neurotoxins Bind to a Muscular-type Nicotinic Acetylcholine Receptor?
J. Biol. Chem.,
July 5, 2002;
277(28):
25741 - 25747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fruchart-Gaillard, B. Gilquin, S. Antil-Delbeke, N. Le Novere, T. Tamiya, P.-J. Corringer, J.-P. Changeux, A. Menez, and D. Servent
Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor
PNAS,
February 20, 2002;
(2002)
42699899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zeng, L. Moise, M. A. Grant, and E. Hawrot
The Solution Structure of the Complex Formed between alpha -Bungarotoxin and an 18-mer Cognate Peptide Derived from the alpha 1 Subunit of the Nicotinic Acetylcholine Receptor from Torpedo californica
J. Biol. Chem.,
June 15, 2001;
276(25):
22930 - 22940.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fruchart-Gaillard, B. Gilquin, S. Antil-Delbeke, N. Le Novere, T. Tamiya, P.-J. Corringer, J.-P. Changeux, A. Menez, and D. Servent
Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor
PNAS,
March 5, 2002;
99(5):
3216 - 3221.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|